Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042

Allarity Therapeutics, Inc.

USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.
Patent term extends into April 2042, providing long-term exclusivity for stenoparib when used with the DRP test.
Patent covers methods to predict clinical benefit from stenoparib based on tumor gene-expression profiles and patient selection.
Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.